7th International Immunoglobulin Conference: Immunomodulation

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• Rheumatoid arthritis (RA) is a severe autoimmune condition requiring aggressive treatment to prevent joint damage.
• Autoimmune diseases like immunobullous skin diseases and recurrent miscarriage (RM) share underlying autoimmune mechanisms.
• Tumor necrosis factor-alpha (TNF-α) levels and human leukocyte antigen (HLA) polymorphisms are implicated in the autoimmune basis of secondary RM.

Purpose of the Study:

• To outline a therapeutic strategy for rheumatoid arthritis (RA) using a combination of non-biological and biological disease-modifying drugs.
• To discuss the potential of intravenous immunoglobulin (IVIg) therapy in managing autoimmune conditions, including immunobullous skin diseases and secondary RM.

Main Methods:

• First-line therapy for RA involves methotrexate, a non-biological disease-modifying antirheumatic drug (DMARD).
• Second-line treatment for RA includes the addition of biological agents.
• Intravenous immunoglobulin (IVIg) therapy is explored as an adjuvant treatment for autoimmune diseases.

Main Results:

• Methotrexate is employed as the initial treatment for RA.
• Biological agents are introduced as a second-line therapy for RA.
• IVIg therapy, often combined with immunosuppressants, can reduce pathogenic autoantibodies in skin diseases.
• IVIg shows potential efficacy in secondary RM, even at low doses.

Conclusions:

• The described therapeutic approach for RA combines conventional and biologic DMARDs.
• IVIg is a potential treatment modality for autoimmune-mediated recurrent miscarriage (RM) and immunobullous skin diseases.
• Further research is needed to elucidate the mechanisms of IVIg in treating these autoimmune conditions.